Literature DB >> 15312352

[Primary central nervous system lymphoma: a report of 28 patients].

Yi Hu1, Feng-yi Feng, Yuan-kai Shi, Li-qiang Zhou, Da-zhong Gu, Qi-lu Wang.   

Abstract

OBJECTIVE: To evaluate the clinical characteristics, reasonable mode of treatment and prognostic factors in patients with primary central nervous system lymphoma (PCNSL).
METHODS: Twenty-eight patients with PCNSL treated from 1989 to 2002 were retrospectively reviewed. The clinical characteristics, results of treatment and prognostic factors were analyzed by SPSS10.0 statistic software.
RESULTS: Of 28 patients, 18 men and 10 women with a median age of 52 years. The median survival time was 2 years (range 6 months-6 years). The 5-year survival rate was 21.4%. Nineteen patients had single-locus lesion and 9 multi-locus lesion, 78.6% of the patients were diagnosed as having B-cell origin, its main type being diffuse large cell lymphoma. According to international working formulation (WF), moderate-grade of histopathology was observed in 57.7% (15/28). Cox regression analysis revealed that single- or multi-locus lesion was only independent prognostic factor (P = 0.0417). Combined chemotherapy showed significant efficacy for those patients who had lesion of B-cell origin, high grade or multi-locus lesion, and the efficacy of irregular chemotherapy was better than that of regular chemotherapy.
CONCLUSION: Primary central nervous system lymphoma has a special prognostic factor. Chemotherapy plays a very important role in comprehensive treatment, irregular chemotherapy should be adopted as a regular treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312352

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  1 in total

1.  Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma.

Authors:  Yi-Xia Wang; Yan Huang; Xiao-Ping Xu; Bo-Bin Chen; Zhi-Guang Lin; Yan Ma; Tian-Ling Ding; Qian Wang
Journal:  Oncol Lett       Date:  2020-01-22       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.